Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Institutes of Health Clinical Center (CC)
Study ID
NCT00047164
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies such as anti-cytotoxic T-lymphocyte-associated antigen-4 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody to see how well it works in treating patients with lymphoma or colon cancer that has not responded to vaccine therapy.

Key Dates

Start date
Sep 30, 2002
Status verified
Mar 2012
Primary completion
Sep 30, 2010
Completion
Nov 30, 2010

Study Design

Enrollment
89 participants (actual)
Primary purpose
TREATMENT

Primary Outcome Measure

Toxicity after every 3 courses of treatment and every month for up to a year after completion of study treatment

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office· Bethesda, MD

Related Studies